Treatment
Tofacitinib clinical trials
We’re tracking 38 recruiting studies that include Tofacitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT03414502RecruitingPhase 3
Predictors of Response to DMARDs in Rheumatoid Arthritis
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
Omaha, NebraskaAges 19 years+ - NCT03976245RecruitingPhase 4
Tested new advanced treatment options for rheumatoid arthritis
This trial studies advanced medicines for rheumatoid arthritis (RA) in people whose RA is still active despite several standard treatments. It may help by testing whether a different advanced option can better control symptoms and joint inflammation.
London, OntarioAges 18 years+ - NCT04743518RecruitingPhase 4
How ulcerative colitis medicines affect blood vessel stiffness
This study looks at how common ulcerative colitis treatments (anti-TNF medicines, vedolizumab, or tofacitinib) change the health of your blood vessels. It may help doctors better understand cardiovascular risk in people with ulcerative colitis.
AmiensAges 18 years+ - NCT04871191RecruitingPhase 3
Salvage treatment for granulomatosis with polyangiitis flare
This Phase 3 trial studies “salvage” treatment for people with active granulomatosis with polyangiitis (GPA) whose standard treatments have not worked well enough. It aims to improve disease control and reduce the need for ongoing higher-dose steroids.
ParisAges 18 years+ - NCT05186623Recruiting
Personalized prediction for ulcerative colitis treatment response
This study builds a prediction model to estimate how people with ulcerative colitis may respond to certain medicines. It may help doctors choose the most effective treatment sooner.
SeoulAges 18–79 - NCT05348213RecruitingPhase 2
Targeted drugs plus R-ICE chemo for relapsed lymphoma
This Phase 2 trial studies targeted drugs combined with R-ICE chemotherapy in people with diffuse large B-cell lymphoma (DLBCL) that has come back or hasn’t responded. It may help shrink the lymphoma after prior treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06119490RecruitingEarly Phase 1
Methylprednisolone and JAK inhibitor for severe skin reaction
This trial tests a combination of a steroid (methylprednisolone) and a JAK inhibitor to treat toxic epidermal necrolysis, a severe skin reaction. The goal is to see if adding the JAK inhibitor helps improve outcomes and safety.
Fuzhou, FujianAges 18–70 - NCT06176508RecruitingPhase 2
New medicine for active psoriatic arthritis
This trial tests a new oral medicine (HS-10374) for people with active psoriatic arthritis who have not responded well to standard treatments. It compares the drug to a placebo to see if it reduces joint pain, swelling, and skin symptoms.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06469424Recruiting
Safety of Tofacitinib in Ulcerative Colitis
This study follows people with moderately to severely active ulcerative colitis who are taking the medication tofacitinib (Xeljanz). It aims to track any safety concerns in a real-world setting, using information already collected in a European registry (UR-CARE).
BonheidenAges 18 years+ - NCT07138898RecruitingPhase 2
Managing immune medications for shoulder replacement in rheumatology patients
This trial tests two ways of managing your immunosuppressant medication around the time of shoulder replacement surgery. The goal is to see if one approach leads to fewer infections while still controlling your rheumatic disease.
New York, New YorkAges 18 years+ - NCT06498089RecruitingPhase 4
Comparing tailored vs. standard treatment for active Takayasu's arteritis.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06573593Recruiting
JAK inhibitors for children with alopecia areata
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
Hangzhou, ZhejiangAges 2–80 - NCT07598643RecruitingPhase 2
Immune System Treatment to Help Down Syndrome Development
This study tests a medication called tofacitinib that modulates the immune system in children and young adults with Down syndrome aged 6–22 years. The goal is to see if it can improve brain development and overall health outcomes over 6 months.
Aurora, ColoradoAges 6–22 - NCT06438679Enrolling by invitationPhase 4
3T therapy for MDA5-positive dermatomyositis with lung involvement
This trial tests a treatment called 3T therapy for people with MDA5-positive dermatomyositis, a rare autoimmune disease that affects the skin, muscles, and often the lungs. The goal is to see if 3T therapy can help control the disease and improve lung function.
Hangzhou, ZhejiangAges 18 years+
Common questions
- Are there clinical trials studying Tofacitinib?
- Yes. Clin2 currently lists 38 recruiting studies that include Tofacitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tofacitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tofacitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tofacitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.